TAIHO PHARMACEUTICAL CO., LTD.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
 
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 89166
 
 
 
C07D HETEROCYCLIC COMPOUNDS 56106
 
 
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 1184
 
 
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 841
 
 
 
C07K PEPTIDES 7129
 
 
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 7199
 
 
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 4163
 
 
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 4121
 
 
 
C07F ACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM, OR TELLURIUM 367
 
 
 
A01K ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS246

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2017/0252,307 DETRUSOR HYPERACTIVITY WITH IMPAIRED CONTRACTILITY AMELIORATING AGENTMay 19, 17Sep 07, 17[A61K]
2017/0216,261 COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCERApr 21, 17Aug 03, 17[A61K]
2017/0217,970 NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOFApr 20, 17Aug 03, 17[C07D]
2017/0202,838 IMMUNOMODULATOROct 28, 16Jul 20, 17[A61K]
2017/0112,866 ANTI-TUMOR AGENT CONTAINING TAXANE COMPOUND, AND ANTI-TUMOR EFFECT ENHANCERApr 03, 15Apr 27, 17[A61K]
2017/0042,875 NOVEL ACETIC ACID ESTER COMPOUND OR SALT THEREOFOct 18, 16Feb 16, 17[A61K]
2017/0044,166 NOVEL SALT OF FUSED PYRIMIDINE COMPOUND AND CRYSTAL THEREOFOct 19, 16Feb 16, 17[C07D]
2016/0193,210 ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITORJul 17, 14Jul 07, 16[A61K]
2016/0082,032 THERAPEUTIC EFFECT PREDICTION METHOD FOR COLORECTAL CANCER PATIENT IN WHOM EXPRESSION OF TK1 PROTEIN HAS INCREASEDMay 16, 14Mar 24, 16[A61K, G01N]
2014/0378,409 EFFECT POTENTIATOR FOR ANTITUMOR AGENTSDec 27, 12Dec 25, 14[A61K]

View all Publication..

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9920060 Pyrazolo[3,4-d]pyrimidine compound or salt thereofApr 20, 17Mar 20, 18[A61K, A01N, C07D]
9907792 Acetic acid ester compound or salt thereofOct 18, 16Mar 06, 18[A61K, C07D, C07B]
9908889 Salt of fused pyrimidine compound and crystal thereofOct 19, 16Mar 06, 18[A61K, C07D]
9889136 Tetrahydropyridopyrimidine compound or salt thereofJul 06, 16Feb 13, 18[A61K, C07D, A61P]
9845329 Method for producing a substituted 6,7,8,9-tetrahydropyrimido[5,4-b]indolizine, substituted 7,8,9,10-tetrahydro-6H-pyrimido[5′,4′:4,5]pyrrolo[1,2-a]azepine and substituted 6,7,8,9,10,11-hexahydropyrimido[5′,4′:4,5]pyrrolo[1,2-a]azocineFeb 21, 14Dec 19, 17[C07F, C07D]
9814724 Antitumor effect potentiator and antitumor agentFeb 17, 17Nov 14, 17[A61K, C07D]
9782392 Azaindole derivativeJan 12, 17Oct 10, 17[A61K, C07D]
9782412 Preventive and/or therapeutic agent of immune diseaseOct 19, 16Oct 10, 17[A61K, C07D]
9758526 Quinoline-substituted compoundDec 19, 16Sep 12, 17[C07D]
9718776 Fluorinated benzilic acid ester compound and salt thereofMay 29, 14Aug 01, 17[C07D]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0035,705 DETRUSOR HYPERACTIVITY WITH IMPAIRED CONTRACTILITY AMELIORATING AGENTAbandonedAug 04, 15Feb 09, 17[A61K]
2016/0151,295 ORAL PARTICULATE ANTITUMOR PREPARATIONAbandonedFeb 01, 16Jun 02, 16[A61K]
9289431 Antitumor effect potentiator composed of imidazooxazine compoundWithdrawnJul 01, 13Mar 22, 16[A61K, C07D]
2015/0110,864 NOVEL ANTITUMOR AGENT COMPRISING COMBINATION OF THREE AGENTSAbandonedMar 15, 13Apr 23, 15[A61K]
2014/0038,966 TEGAFUR-CONTAINING COMPOSITION FOR SINGLE DAILY AND ALTERNATE-DAY DOSINGAbandonedJan 30, 12Feb 06, 14[A61K]
8642572 Cytidine derivative-containing antitumor agent for continuous intravenous administrationExpiredApr 04, 08Feb 04, 14[A61K, C07H]
8598188 Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancerExpiredMar 08, 10Dec 03, 13[A61K]
8586561 Anti-tumor agent comprising cytidine derivative and carboplatinExpiredMar 26, 09Nov 19, 13[A61K, A01N]
8557791 Anti-tumor agent comprising cytidine derivative and carboplatinWithdrawnMar 26, 09Oct 15, 13[A61K, A01N]
8440398 Method for prediction of sensitivity to 5-fluorouracil-type anticancer agentExpiredJan 23, 07May 14, 13[C12Q]
2013/0116,298 ANTITUMOR AGENT OR POSTOPERATIVE ADJUVANT CHEMOTHERAPEUTIC AGENT FOR HEPATOCELLULAR CARCINOMA TREATMENTAbandonedDec 24, 10May 09, 13[A61K]
2013/0078,309 ORAL PARTICULATE ANTITUMOR PREPARATIONAbandonedNov 19, 12Mar 28, 13[A61K]
8329150 Method of evaluating evenness of suplatast tosilate crystal, even crystal, and process for producing the sameExpiredFeb 24, 11Dec 11, 12[A61K, C07C, G01N, A61P]
2012/0277,264 ANTITHROMBOTIC AGENTAbandonedNov 25, 10Nov 01, 12[A61K, C07C, A61P]
2012/0264,803 METHOD FOR PREDICTING THERAPEUTIC EFFECTS OF CHEMOTHERAPY ON HEPATOCELLULAR CARCINOMA PATIENTSAbandonedDec 24, 10Oct 18, 12[A61K, C12Q, C07D, A61P]
8247458 Therapeutic agent for diabetic neuropathyExpiredDec 20, 07Aug 21, 12[A61K, A01N, C07C]
8188105 Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredientExpiredOct 10, 08May 29, 12[A61K]
2012/0059,009 ANTI-TUMOR AGENT CONTAINING TEGAFUR-GIMERACIL-OTERACIL POTASSIUM COMBINATION DRUG AND OXALIPLATINAbandonedMay 11, 10Mar 08, 12[A61K, A61P]
8058261 3′-ethynylcytidine derivativeExpiredJul 23, 07Nov 15, 11[A61K, A01N]
2011/0172,184 ANTITUMOR AGENT CONTAINING 4 - [[3,5 - BIS (TRIMETHYLSILYL) BENZOYL] AMINO] BENZOIC ACIDAbandonedSep 15, 09Jul 14, 11[A61K, A61P]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.